Equities

Argenica Therapeutics Ltd

Argenica Therapeutics Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.74
  • Today's Change0.015 / 2.07%
  • Shares traded30.49k
  • 1 Year change+60.87%
  • Beta1.0346
Data delayed at least 20 minutes, as of Nov 22 2024 03:01 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Argenica Therapeutics Limited is an Australia-based biotechnology company, developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. The Company's lead neuroprotective peptide candidate, ARG-007, has been demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischemic encephalopathy (HIE). The Company has initiated a Phase 2 clinical trial in acute ischemic stroke patients, as well as continuing to generate preclinical data in other neurological conditions.

  • Revenue in AUD (TTM)192.09k
  • Net income in AUD-5.48m
  • Incorporated2019
  • Employees--
  • Location
    Argenica Therapeutics Ltd4/117 BroadwayNEDLANDS 6009AustraliaAUS
  • Phone+61 89329-3396
  • Websitehttps://argenica.com.au/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
IDT Australia Limited14.12m-5.41m45.13m156.00--1.57--3.20-0.0154-0.01540.04040.06670.47341.842.62---18.15-9.77-22.59-11.6180.1184.61-38.33-23.121.12-50.050.1601--100.813.0936.30---10.39--
Anteotech Ltd514.89k-8.88m52.04m40.00--8.91--101.06-0.0039-0.00390.00020.00210.0699--2.55---120.47-75.24-159.35-84.74-----1,724.74-1,444.66----0.3055--26.8527.9329.82--68.39--
Tryptamine Therapeutics Ltd-100.00bn-100.00bn57.65m----9.52----------0.0049----------------------------0.0342--------------
Neurotech International Ltd3.34m-5.07m68.29m----5.64--20.47-0.0054-0.00540.00370.01170.38070.0011.59---57.86-134.56-63.92-163.66100.00---151.98-462.3838.81--0.00--165.9867.3934.94------
Actinogen Medical Ltd291.02k-13.04m77.07m----3.45--264.82-0.0061-0.00610.00010.00720.0159--0.0433---71.44-48.56-78.20-51.97-----4,482.26-5,188.44---163.100.0159---20.637.31-21.32------
Percheron Therapeutics Ltd615.48k-11.92m80.87m8.00--7.51--131.39-0.0135-0.01350.00070.01040.045--0.2912---87.09-75.92-122.82-89.91-----1,936.57-4,028.81---1,956.650.0042--59.9056.21-4.74------
Proteomics International LaboratoriesLtd1.41m-6.38m89.08m----9.46--63.19-0.0507-0.05070.01120.07190.1346--6.45---61.88-60.46-67.65-69.49-----459.82-290.18---208.630.0331---4.24-1.45-3.23--60.39--
Argenica Therapeutics Ltd192.09k-5.48m89.66m----6.21--466.79-0.0518-0.05180.00190.11280.0148--0.7326---42.28---50.70-------2,852.56-----21,829.870.00--214.90---13.80------
Paradigm Biopharmaceuticals Ltd6.52m-58.65m97.99m----4.12--15.03-0.1875-0.18750.01860.0680.138--1.10---124.19-52.89-150.28-58.0699.86---899.60-543.63---961.470.006---23.2214.97-12.99------
LTR Pharma Ltd49.00k-6.95m103.44m----57.84--2,111.07-0.0499-0.04990.00040.0211---------------------14,192.84-----414.020.00-------378.00------
Data as of Nov 22 2024. Currency figures normalised to Argenica Therapeutics Ltd's reporting currency: Australian Dollar AUD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.